Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report Download FREE Resources

Published: October 01, 2026 Report Code: GDHC346PIDR-8M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

Analyze the Alzheimer’s Disease therapeutics market across eight major markets with revenue forecasts, pipeline analysis, disease-modifying therapies, competitive dynamics, unmet needs, and outlook through 2033.

This report covers the 8 major markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033.

GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβ monoclonal antibodies (mAbs) across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2 million (38.8%), respectively. The smallest market is France, contributing only 1.1% to total global sales, due to the lower AD prevalent population in the country, as well as the lack of reimbursement of the current AD symptomatic therapies resulting in lower treatment rates in France.
By the end of the forecast period in 2033, GlobalData projects AD sales to rise to $14.7 billion in the 8MM, at a compound annual growth rate (CAGR) of 20.0%.

Scope

Overview of Alzheimer’s Disease, including epidemiology, symptoms, diagnosis, and disease management.

Annualized Alzheimer’s Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Alzheimer's therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Alzheimer's treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global Alzheimer’s Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 8MM Alzheimer’s Disease therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM Alzheimer’s Disease therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Eli Lilly and Co
Otsuka Pharmaceutical Co Ltd
Novartis AG
Biogen Inc
Eisai Co Ltd
Suven Life Sciences Ltd
Towa Pharmaceutical Co Ltd
AB Science SA
H. Lundbeck AS
Neurimmune Holding AG
Annovis Bio Inc
Teikoku Seiyaku Co Ltd
AbbVie Inc
BioVie Inc
Alzheon Inc
Axsome Therapeutics Inc
TauRx Pharmaceuticals Ltd
Anavex Life Sciences Corp
Shanghai Green Valley Pharmaceutical Co Ltd
Johnson & Johnson
Corium LLC
Bristol-Myers Squibb Co
Ono Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
AriBio Co Ltd
Luye Pharma Group Ltd
BioXcel Therapeutics Inc
AlphaCognition Inc
Biomed Industries Inc
Cerecin Inc

List of Contents

List of Tables

List of Figures

1 Alzheimer’s Disease: Executive Summary

1.1 Summary of changes

1.2 Executive summary

1.3 Alzheimer’s market forecast to see double-digit sales growth out to 2033

1.4 Eisai, Biogen, and Lilly are forecast to lead the AD market in 2033

1.5 Opportunities to fulfil key unmet needs will remain

1.6 Novel late-stage pipeline drugs will be a key driver of growth

1.7 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology

3.1.1 Risk genes

3.1.2 Deterministic genes

3.1.3 Protective genes

3.1.4 Metabolic disruption

3.2 Pathophysiology

3.2.1 Structural changes in the brain

3.2.2 Degenerative process

3.2.3 Aβ plaques

3.2.4 Neurofibrillary tangles

3.2.5 Neurotransmitter deficiencies

3.2.6 Oxidative stress

3.3 Biomarkers / targets of interest

3.4 Disease staging systems

3.5 Symptoms and prognosis

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast assumptions and methods: total prevalent cases of AD by DSM-IV criteria

4.4.4 Forecast assumptions and methods: total prevalent cases of AD by severity

4.4.5 Forecast assumptions and methods: total prevalent cases of preclinical AD

4.4.6 Forecast assumptions and methods: total prevalent cases of MCI

4.5 Epidemiological Forecast for AD (2023-33)

4.5.1 Total prevalent cases of AD by DSM-IV criteria

4.5.2 Age-specific total prevalent cases of AD by DSM-IV criteria

4.5.3 Sex-specific total prevalent cases of AD by DSM-IV criteria

4.5.4 Total prevalent cases of AD by severity

4.5.5 Total prevalent cases of preclinical AD

4.5.6 Age-specific total prevalent cases of preclinical AD

4.5.7 Sex-specific total prevalent cases of preclinical AD

4.5.8 Total prevalent cases of MCI

4.5.9 Age-specific total prevalent cases of MCI

4.5.10 Sex-specific total prevalent cases of MCI

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 More efficacious DMTs

7.3 Improved control of behavioral symptoms

7.4 Symptomatic drugs for cognition

7.5 Improving diagnosis earlier in the disease progression

7.6 Access to treatment

8 R&D Strategies

8.1 Overview

8.1.1 Targeting Aβ

8.1.2 Novel MOAs

8.1.3 Targeting agitation and psychosis

8.1.4 Targeting preclinical AD

8.1.5 Combination therapies

8.1.6 Non-pharmacological treatments

8.2 Clinical Trials Design

8.2.1 Inclusion/exclusion criteria

8.2.2 Endpoints

8.2.3 Use of biomarkers in trial design

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Potential DMTs

10.2.2 Therapies for agitation and psychosis associated with AD

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

12.5 China

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 AD clinical development pipeline

13.4 Methodology

13.4.1 Forecasting methodology

13.5 Primary research – KOLs interviewed for this report

13.6 Primary research – prescriber survey

13.7 About the authors

13.7.1 Analyst

13.7.2 Therapy Area Director

13.7.3 Epidemiologist

13.7.4 Managing Epidemiologist

13.7.5 Vice President of Disease Intelligence and Epidemiology

13.7.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: Summary of changes to the Alzheimer’s Disease: Eight-Market Drug Forecast and Analysis – Update Report

Table 2: Alzheimer’s disease: Key metrics in the 8MM

Table 3: Categorization of fluid analyte and imaging biomarkers

Table 4: Intended uses for imaging, CSF and plasma biomarker assays

Table 5: Clinical staging for individuals on the Alzheimer's disease continuum

Table 6: The seven-stage Reisberg scale of AD

Table 7: Common symptoms of AD across three main clinical stages

Table 8: Risk factors and comorbidities for AD

Table 9: Summary of NINCDS-ARDA diagnostic criteria for AD

Table 10: Treatment guidelines for AD

Table 11: Context of use for biomarkers in AD clinical trials

Table 12: Top 10 deals by value, 2016–26

Table 13: AD market – global drivers and barriers, 2023–33

Table 14: Key events impacting sales for AD in the US, 2023–33

Table 15: AD market – drivers and barriers in the US, 2023–33

Table 16: Key events impacting sales for AD in the 5EU, 2023–33

Table 17: AD market – drivers and barriers in the 5EU, 2023–33

Table 18: Key events impacting sales for AD in Japan, 2023–33

Table 19: AD market – drivers and barriers in Japan, 2023–33

Table 20: Key events impacting sales for AD in China, 2023–33

Table 21: AD market – drivers and barriers in China, 2023–33

Table 22: AD clinical development pipeline by drug class

Table 23: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global AD sales forecast by country, in 2023 and 2033

Figure 2: Analysis of the company portfolio gap in AD during the forecast period

Figure 3: Competitive assessment of the late-stage potential DMTs that GlobalData expects to be licensed for the treatment of AD during the forecast period

Figure 4: 8MM, total prevalence of AD by DSM-IV criteria (%), men and women, ages ≥65 years, 2023

Figure 5: 8MM, total prevalence of preclinical AD (%), men and women, ages ≥55 years, 2023

Figure 6: 8MM, total prevalence of MCI (%), men and women, ages ≥65 years, 2023

Figure 7: 8MM, sources used and not used to forecast the total prevalent cases of AD by DSM-IV criteria

Figure 8: 8MM, sources used to forecast the total prevalent cases of AD by severity

Figure 9: 8MM, sources used to forecast the total prevalent cases of preclinical AD

Figure 10: 8MM, sources used to forecast the total prevalent cases of MCI

Figure 11: 8MM, total prevalent cases of AD by DSM-IV criteria, N, both sexes, ages ≥65 years, 2023

Figure 12: 8MM, total prevalent cases of AD by DSM-IV criteria by age, N, both sexes, 2023

Figure 13: 8MM, total prevalent cases of AD by DSM-IV criteria by sex, N, ages ≥65 years, 2023

Figure 14: 8MM, total prevalent cases of AD by severity, N, both sexes, ages ≥65 years, 2023

Figure 15: 8MM, total prevalent cases of preclinical AD, N, both sexes, ages ≥55 years, 2023

Figure 16: 8MM, total prevalent cases of preclinical AD by age, N, both sexes, 2023

Figure 17: 8MM, total prevalent cases of preclinical AD by sex, N, ages ≥55 years, 2023

Figure 18: 8MM, total prevalent cases of MCI, N, both sexes, ages ≥65 years, 2023

Figure 19: 8MM, total prevalent cases of MCI by age, N, both sexes, 2023

Figure 20: 8MM, total prevalent cases of MCI by sex, N, ages ≥65 years, 2023

Figure 21: 8MM, disease management timeline for AD

Figure 22: 8MM, treatment algorithm for AD

Figure 23: Unmet needs and opportunities in AD

Figure 24: Overview of the development pipeline in AD

Figure 25: Key late-stage trials for the promising potential DMTs that GlobalData expects to be licensed for AD in the 8MM during the forecast period

Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for agitation/psychosis associated with AD in the 8MM during the forecast period

Figure 27: Competitive assessment of the pipeline potential DMTs benchmarked against Leqembi (lecanemab)

Figure 28: Competitive assessment of the pipeline anti-agitation and anti-psychosis drugs benchmarked against Risperdal (risperidone)

Figure 29: Analysis of the company portfolio gap in AD during the forecast period

Figure 30: Global (8MM) sales forecast by country for AD in 2023 and 2033

Figure 31: Global (8MM) sales forecast by drug class for AD in 2023 and 2033

Figure 32: Sales forecast by class for AD in the US in 2023 and 2033

Figure 33: Sales forecast by drug class for AD in the 5EU in 2023 and 2033

Figure 34: Sales forecast by drug class for AD in Japan in 2023 and 2033

Figure 35: Sales forecast by drug class for AD in China in 2023 and 2033

Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports

Pharmaceuticals

New

Alzheimer’s Disease in 68 Markets: Disease Overview, Product Profiles, Patient…

Pharmaceuticals

New

Parkinson's Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet…

Pharmaceuticals

New

Acute-on-Chronic Liver Failure: Market View, Current and Future Competitive Landscape

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

Access a live Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports